Physicochemical Properties
| Molecular Formula | C28H24N4O2 |
| Molecular Weight | 448.526 |
| Exact Mass | 448.189 |
| CAS # | 1402727-29-0 |
| PubChem CID | 66571561 |
| Appearance | Light yellow to khaki solid powder |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 747.7±60.0 °C at 760 mmHg |
| Flash Point | 249.8±23.1 °C |
| Vapour Pressure | 0.0±2.4 mmHg at 25°C |
| Index of Refraction | 1.768 |
| LogP | 5.47 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 8 |
| Heavy Atom Count | 34 |
| Complexity | 685 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | COC1=C(C=CC(=C1)OCC2=CC=CC=N2)/C=C/C3=CC(=NN3)/C=C/C4=CC5=C(C=C4)C=CN5 |
| InChi Key | AMBZHNVCLPHAKA-NSJFVGFPSA-N |
| InChi Code | InChI=1S/C28H24N4O2/c1-33-28-18-26(34-19-25-4-2-3-14-29-25)12-9-22(28)8-11-24-17-23(31-32-24)10-6-20-5-7-21-13-15-30-27(21)16-20/h2-18,30H,19H2,1H3,(H,31,32)/b10-6+,11-8+ |
| Chemical Name | 6-[(E)-2-[5-[(E)-2-[2-methoxy-4-(pyridin-2-ylmethoxy)phenyl]ethenyl]-1H-pyrazol-3-yl]ethenyl]-1H-indole |
| Synonyms | PE 859; PE-859; PE859 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In a concentration-dependent manner, PE859 prevents full-length tau aggregation and 3RMBD caused by heparin. The last measurement cycle's estimated IC50 values for each assay were 2.23 μM and 0.81 μM, respectively. PE859 forms β-sheet structures that prevent tau aggregation [2]. |
| ln Vivo | PE859 has the ability to penetrate the blood-brain barrier and permeate into central nervous system tissues. PE859 reached its maximal concentrations in the blood at 2.005 μg/mL and the brain at 1.428 μg/g after three and six hours, respectively. In JNPL3 mice, PE859 postpones the onset and development of motor impairment. PE859 inhibits the aggregation of tau protein that is sarkosyl-insoluble, hence delaying the evolution of motor dysfunction. [2] |
| References |
[1]. Design and synthesis of curcumin derivatives as tau and amyloid β dual aggregation inhibitors. Bioorg Med Chem Lett. 2016 Oct 15;26(20):5024-5028. [2]. PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo. PLoS One. 2015 Feb 6;10(2):e0117511. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~50 mg/mL (~111.48 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2295 mL | 11.1475 mL | 22.2951 mL | |
| 5 mM | 0.4459 mL | 2.2295 mL | 4.4590 mL | |
| 10 mM | 0.2230 mL | 1.1148 mL | 2.2295 mL |